AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02664012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Menthol Cigarette #3
Description: VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
Study NCT02664012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. Nicotine Gum
Description: 4 mg nicotine polacrilex gum
Study NCT01342575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative exposure maneuvers
Description: * Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~* Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~* Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~* Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~* Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed
Study NCT04612283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NGA-01 gel
Description: NGA-01 is a gel formulation with mostly herbal active ingredients
Study NCT04612283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo with no active ingredients
Study NCT02368132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Delivered TEP
Description: All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
Study NCT02368132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Delivered TEP
Description: Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
Study NCT00500578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Arm 1 = 6 Grams Over 18 hours Every 24 Hours
Study NCT00500578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
Study NCT04635930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping plus Traditional exercises
Description: The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
Study NCT04635930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taping plus Traditional exercises
Description: The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
Study NCT02404870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02404870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
Study NCT05447845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized visual acuity assessment program
Description: Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
Study NCT01756365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical transplantation of ACCE
Description: The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
Study NCT02479659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV testing commodity reinforcement
Description: HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
Study NCT04584476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superior capsular reconstuction
Description: these patients underwent arthroscopic superior capsular reconstuction
Study NCT04584476 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial rotator cuff repair
Description: these patients underwent arthroscopic partial rotator cuff repair
Study NCT02479659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Policy reinforcement meeting
Description: District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
Study NCT02479659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-out HIV testing for mothers and newborns
Description: Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~* If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~* If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner.
Study NCT02479659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operational support for service integration
Description: The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
Study NCT02479659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community sensitization
Description: Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
Study NCT03816553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
Study NCT03816553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib will be administered 250mg orally, once daily until progression.
Study NCT01081782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: 0.15 mg once per day for 26 weeks
Study NCT01081782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: 0.1 mg once per day for 26 weeks
Study NCT01081782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: 0.05 mg once per day for 26 weeks
Study NCT01081782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-4641 placebo
Description: Placebo once per day for 26 weeks
Study NCT04010461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
Study NCT04010461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back working memory task
Description: Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
Study NCT03410992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be provided at pre-specified time intervals.
Study NCT03410992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study NCT03410992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study NCT03044847 — intervention group
Intervention type: OTHER
Intervention: COPD group
Description: The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
Study NCT01042834 — intervention group
Intervention type: OTHER
Intervention: Air pollution study on healthy volunteers.
Description: The subjects are examined three times:~* First the volunteers get used to equipments.~* Second and third the volunteers sleep in a pollution or purified air.
Study NCT02912221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
Study NCT02937181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: IV Ceftaroline will be given for 72 hours
Study NCT03021317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHar
Description: The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
Study NCT04378569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.3%
Description: ARQ-252 cream 0.3%
Study NCT04378569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.1%
Description: ARQ-252 cream 0.1%
Study NCT04378569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-252 Vehicle Cream
Description: ARQ-252 Vehicle Cream
Study NCT02121171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen Collagen Matrix
Description: Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
Study NCT02121171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined trabeculotomy-trabeculectomy
Description: Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
Study NCT03235037 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levodopa
Description: The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
Study NCT01243060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almorexant
Description: 100mg
Study NCT01243060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almorexant
Description: 200mg
Study NCT01243060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem 10mg
Description: 10mg
Study NCT01243060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-time dose of Placebo
Study NCT00715234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder/recall notices for vaccines
Description: 1. Receive a generic letter reminding them to make an appointment to get vaccines.~2. Receive a computer-generated telephone message at 1 week post initial letter.~3. Receive a computer-generated telephone message at 2 months post initial letter.~4. Receive a letter at 3 months post initial letter.
Study NCT01061541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB low thio /
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.
Study NCT01061541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib 2.5
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.
Study NCT01061541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.
Study NCT01061541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.
Study NCT01061541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unconjugated Hib vaccine (plain PRP)
Description: One dose as intramuscular injection at 10 months of age
Study NCT01061541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unconjugated Hib vaccine (plain PRP)
Description: One dose as intramuscular injection at 10 months of age
Study NCT01151345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILACEM
Description: At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
Study NCT01151345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANGIOTROFIN
Description: At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
Study NCT01985100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen chamber
Study NCT00705757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost
Description: Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
Study NCT00705757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost
Description: Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
Study NCT00705757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost
Description: Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
Study NCT02914535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02914535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s) administered orally once daily
Study NCT02914535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s) administered orally once daily
Study NCT04399369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% silver diamine fluoride solution
Study NCT04399369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: 5% sodium fluoride varnish
Study NCT03522818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual Trigger
Description: Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
Study NCT03522818 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal
Description: Will use the alarm as provided by the manufacture.
Study NCT00718094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E®
Description: Oral capsules
Study NCT00718094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral tablet: placebo
Study NCT00005032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Study NCT00005032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT04006470 — intervention group
Intervention type: DRUG
Intervention: Stannous fluoride dentifrice
Description: Stannous fluoride (0.454%) dentifrice
Study NCT04006470 — intervention group
Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing potassium nitrate or arginine.
Study NCT04006470 — intervention group
Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study NCT01451918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: 500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
Study NCT01451918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: 500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
Study NCT02899975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Validation
Description: Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
Study NCT04986774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue intracranial stenting
Description: Rescue Intracranial Stenting in Acute Ischemic Stroke caused by intracranial large vessel occlusion
Study NCT04832256 — intervention group
Intervention type: DEVICE
Intervention: Radical-7 Pulse CO-Oximeter
Description: COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
Study NCT01218542 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy
Description: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
Study NCT02413957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation
Description: Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
Study NCT02413957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
Study NCT01015716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention-group
Description: Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
Study NCT01015716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-group
Description: Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
Study NCT03289767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curved-tube
Description: Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily.
Study NCT01038687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets